FibroGen Announces Fiscal 2015 Financial Results
29 févr. 2016 16h02 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 29, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today reported financial results for the year ended December...
Rockwell Medical Files IND to Investigate Triferic for Rare Orphan Disease Iron-Refractory, Iron-Deficiency Anemia (IRIDA)
22 févr. 2016 08h00 HE
|
Rockwell Medical, Inc.
WIXOM, Mich., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney...
FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat’s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease
16 févr. 2016 07h20 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 16, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today announced that the American Journal of Kidney Disease...
FibroGen Announces Third Quarter 2015 Financial Results
12 nov. 2015 16h02 HE
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 12, 2015 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today reported financial results for the quarter ended...
Phase 2 Data for Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Show Anemia Correction in Incident Dialysis Chronic Kidney Disease Patients Regardless of Iron Repletion Status, Iron Supplementation Regimen, or Dialysis Modality
22 oct. 2015 19h14 HE
|
FibroGen, Inc.
SAN FRANCISCO, Oct. 22, 2015 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, along with its partner, AstraZeneca (NYSE:AZN), today...
HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
04 nov. 2008 09h00 HE
|
HemaQuest Pharmaceuticals
BOSTON, MA--(Marketwire - November 4, 2008) - HemaQuest Pharmaceuticals today announced that
the U.S. Food and Drug Administration (FDA) has awarded the company orphan
drug designations for sickle...
HemaQuest Announces Initiation of Phase I Clinical Trial of HQK-1001 to Treat Hemoglobin Disorders
17 janv. 2008 09h00 HE
|
HemaQuest Pharmaceuticals
NEWTON, MA--(Marketwire - January 17, 2008) - HemaQuest Pharmaceuticals, which received its
first round of venture financing three months ago, today announced that the
U.S. Food and Drug...
HemaQuest Announces $20M Series A Financing for Anemia Drug Development
01 nov. 2007 10h30 HE
|
HemaQuest Pharmaceuticals
NEWTON, MA--(Marketwire - November 1, 2007) - HemaQuest Pharmaceuticals, a new company
developing proprietary small molecule therapeutics to treat serious blood
disorders, today announced that it...